we can get a feel for how investor attitudes to a company have morphed over time. During five years of share price growth, Cencora achieved compound earnings per share (EPS) growth of 18% per year.

Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised ... The Conshohocken, Pennsylvania-based company now expects its 2025 adjusted profit to range between $15.25 and $15. ...

Key Indicators: Cencora's Financial Health Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong ...

For the next fiscal year, the company is expected to earn $16.52 per share on $339.6 billion in revenues. This represents a year-over-year change of 9.52% and 6.76%, respectively. Cencora may be ...

Cencora is updating its outlook for fiscal year 2025. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2025 Expectations. Adjusted diluted ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

CONSHOHOCKEN, Pa. — Cencora, Inc. (COR) on Wednesday reported fiscal first-quarter net income of $488.6 million. The Conshohocken, Pennsylvania-based company said it had profit of $2.50 per share.

Cencora is updating its outlook for fiscal year 2025. The Company does not provide forward-looking guidance on a GAAP basis as discussed below in Fiscal Year 2025 Expectations. Adjusted diluted EPS ...

CONSHOHOCKEN, Pa., February 05, 2025--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 ...